<DOC>
	<DOCNO>NCT02635789</DOCNO>
	<brief_summary>The purpose trial evaluate efficacy safety NPC-12G gel ( topical formulation sirolimus ) versus placebo gel facial angiofibroma skin lesion patient tuberous sclerosis complex ( TSC )</brief_summary>
	<brief_title>Phase III Trial Topical Formulation Sirolimus Skin Lesions Patients With Tuberous Sclerosis Complex ( TSC )</brief_title>
	<detailed_description>Tuberous Sclerosis Complex ( TSC ) autosomal dominant hereditary disease cause benign tumor almost whole body ( include skin , brain , kidney , lung heart ) , behavior disorder autism , mental retardation neurologic symptom epilepsy . Angiofibroma TSC-specific facial skin lesion , hamartoma cause increase component skin connective tissue blood vessel . Other skin lesion due TSC white macule ( hypomelanotic macule ) , plaque , shagreen patch ungual fibroma . Current therapeutic method angiofibroma laser surgical treatment , problem many relapse , deficiency evidence , change pigment , scar risk infection . This multicenter , double-blind , randomize , placebo-controlled parallel group trial . The trial three phase ; screen phase , double-blinded treatment phase , post-treatment phase . The screen phase comprises screen visit subject 's initial eligibility evaluate . During double-blinded treatment phase , patient meet entry criterion trial randomize two group , apply 0.2 % NPC-12G gel placebo gel topically twice day 12 week .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient 3 year old great time inform consent 2 . Patients diagnose definite diagnosis accord diagnostic criterion tuberous sclerosis complex ( International Tuberous Sclerosis Complex Consensus Conference 2012 ) 3 . Patients three papule angiofibroma ( &gt; = 2 mm diameter redness ) face screen test 4 . Patients suitable therapy laser surgery , want therapy laser surgery 5 . Patients his/her guardian give write informed consent understand willingness receive enough explanation test drug current trial plan 1 . Patients hard apply test drug topically keep compliance 2 . Patients clinical finding erosion , ulcer eruption around lesion angiofibroma , may affect assessment safety efficacy 3 . Patients hard take picture lesions adequately case may follow instruction stillness 4 . Patients history hypersensitivity alcohol allergy sirolimus 5 . Patients complication malignant tumor , infection , serious heart disease , hepatic function disorder , renal function disorder blood disorder severity consider investigator grade 2 severe reference `` Concerning classification criterion seriousness adverse drug reaction medical agent '' 6 . Patients complication disease unsuitable trial participation , example , uncontrolled diabetes ( fast blood glucose level &gt; 140 mg/dL postprandial blood glucose level &gt; 200 mg/dL ) , dyslipidemia ( cholesterol level &gt; 300 mg/dL &gt; 7.75 mmol/L , triglyceride level &gt; 300 mg/dL &gt; 3.42 mmol/L ) , etc . 7 . Patients take drug mTOR inhibitory action include sirolimus , everolimus temsirolimus within 12 month initial registration 8 . Patients applied topical tacrolimus lesion angiofibroma within 3 month initial registration 9 . Patients receive therapy laser surgery lesion angiofibroma within 6 month initial registration 10 . Female patient may pregnancy lactate 11 . Patients agree take appropriate measure contraception completion posttreatment phase followup period discontinuation inform consent 12 . Patients participate clinical trial take trial drug within 6 month initial registration 13 . Others , patient consider investigator unsuitable participation trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Skin lesion</keyword>
	<keyword>TSC</keyword>
	<keyword>Tuberous Sclerosis Complex</keyword>
	<keyword>NPC-12G</keyword>
	<keyword>Angiofibroma</keyword>
	<keyword>Hypomelanotic macule</keyword>
	<keyword>Plaque</keyword>
</DOC>